BioCryst Pharmaceuticals Highly Volatile

Loading...
Loading...

Baker Brothers Advisors, a hedge fund run by Julian and Felix Baker, disclosed after Monday's market close it acquired 106,800 shares of BioCryst Pharmaceuticals, Inc. BCRX for $7.28 per share.

BioCryst Pharmaceuticals is a biotechnology company that develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. Its stock closed at $7.49 on Monday.

Shares of BioCryst were trading near the $8.00 level during Tuesday's pre-market session. The stock opened for trading at $7.61 and hit an intra-morning high of $7.68 before reversing direction. After 50 minutes of trading, shares of BioCryst were trading lower by 3.47 percent at $7.23.

Posted In: Hedge FundsIntraday UpdateMoversGeneralBaker BrosBaker Brothers Advisorsbiocrystpharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...